Farallon Capital Management LLC Acquires 278,700 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Farallon Capital Management LLC increased its holdings in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 12.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 2,570,700 shares of the company's stock after purchasing an additional 278,700 shares during the period. Farallon Capital Management LLC owned 4.71% of Voyager Therapeutics worth $14,576,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Dimensional Fund Advisors LP raised its position in shares of Voyager Therapeutics by 24.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company's stock valued at $7,828,000 after purchasing an additional 275,571 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Voyager Therapeutics during the fourth quarter worth approximately $746,000. ADAR1 Capital Management LLC boosted its holdings in shares of Voyager Therapeutics by 212.0% during the fourth quarter. ADAR1 Capital Management LLC now owns 126,792 shares of the company's stock worth $719,000 after acquiring an additional 86,158 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Voyager Therapeutics during the fourth quarter worth approximately $267,000. Finally, Barclays PLC boosted its holdings in shares of Voyager Therapeutics by 55.8% during the third quarter. Barclays PLC now owns 104,462 shares of the company's stock worth $612,000 after acquiring an additional 37,398 shares during the period. Institutional investors own 48.03% of the company's stock.

Insider Buying and Selling at Voyager Therapeutics

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 10,885 shares of the stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total value of $37,335.55. Following the completion of the sale, the chief executive officer now owns 430,931 shares in the company, valued at approximately $1,478,093.33. This trade represents a 2.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 6.39% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on VYGR. Canaccord Genuity Group reduced their price objective on Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, March 13th. HC Wainwright reiterated a "buy" rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. Wells Fargo & Company set a $10.00 price target on shares of Voyager Therapeutics and gave the company an "overweight" rating in a research report on Wednesday, March 12th. Wedbush reiterated an "outperform" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $13.97.

Voyager Therapeutics Trading Down 2.7%

Shares of VYGR traded down $0.09 on Wednesday, reaching $3.19. The company's stock had a trading volume of 187,828 shares, compared to its average volume of 445,905. Voyager Therapeutics, Inc. has a twelve month low of $2.75 and a twelve month high of $9.55. The stock has a market capitalization of $176.52 million, a PE ratio of 4.49 and a beta of 0.95. The firm has a fifty day moving average of $3.49 and a 200-day moving average of $4.88.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.18). The firm had revenue of $6.47 million during the quarter, compared to analysts' expectations of $13.55 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. As a group, equities analysts anticipate that Voyager Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.